• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

循环 DNA：非小细胞肺癌患者总生存期的诊断工具和预测标志物。

Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients.

机构信息

Molecular Oncology Group Investigation Center, Portuguese Institute of Oncology, Porto, Portugal.

出版信息

PLoS One. 2012;7(6):e38559. doi: 10.1371/journal.pone.0038559. Epub 2012 Jun 12.

DOI:10.1371/journal.pone.0038559
PMID:22701665
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3373551/
Abstract

PURPOSE

The purpose of our study was to determine whether the amounts of circulating DNA (cDNA) could discriminate between NSCLC patients and healthy individuals and assess its value as a prognostic marker of this disease.

METHODS

We conducted a study of 309 individuals and the cDNA levels were assessed through real-time PCR methodology.

RESULTS

We found increased cDNA levels in NSCLC patients compared to control individuals. We also found a decreased overall survival time in patients presenting high cDNA levels, when compared to lower cDNA concentrations.

CONCLUSIONS

Quantification of cDNA may be a good tool for NSCLC detection with potential for clinical applicability.

摘要

目的

我们研究的目的是确定循环 DNA(cDNA)的含量是否可以区分 NSCLC 患者和健康个体，并评估其作为该疾病预后标志物的价值。

方法

我们进行了一项 309 人的研究，并通过实时 PCR 方法评估了 cDNA 水平。

结果

与对照组个体相比，我们发现 NSCLC 患者的 cDNA 水平升高。我们还发现，与较低的 cDNA 浓度相比，高 cDNA 水平的患者总体生存时间缩短。

结论

cDNA 的定量可能是一种用于 NSCLC 检测的良好工具，具有潜在的临床应用价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/811b/3373551/34cf1c122520/pone.0038559.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/811b/3373551/6b1c081e80d7/pone.0038559.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/811b/3373551/c21a74c47ae9/pone.0038559.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/811b/3373551/34cf1c122520/pone.0038559.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/811b/3373551/6b1c081e80d7/pone.0038559.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/811b/3373551/c21a74c47ae9/pone.0038559.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/811b/3373551/34cf1c122520/pone.0038559.g003.jpg

相似文献

1
Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients.循环 DNA：非小细胞肺癌患者总生存期的诊断工具和预测标志物。
PLoS One. 2012;7(6):e38559. doi: 10.1371/journal.pone.0038559. Epub 2012 Jun 12.
2
Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.循环 DNA 是晚期非小细胞肺癌患者有用的预后因素。
J Thorac Oncol. 2011 Feb;6(2):286-90. doi: 10.1097/JTO.0b013e31820189a5.
3
Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.上皮特异性甲基化标志物：晚期非小细胞肺癌潜在的血浆生物标志物。
J Thorac Oncol. 2011 Nov;6(11):1818-25. doi: 10.1097/JTO.0b013e318226b46f.
4
Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.血清 microRNA-365 及其靶基因 TTF-1 联合作为非小细胞肺癌的一种非侵入性预后标志物。
Biomed Pharmacother. 2015 Oct;75:185-90. doi: 10.1016/j.biopha.2015.07.026. Epub 2015 Aug 31.
5
Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer.游离循环肿瘤DNA的定量分析作为乳腺癌的诊断标志物
DNA Cell Biol. 2008 Aug;27(8):415-21. doi: 10.1089/dna.2008.0744.
6
Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.血清硫氧还蛋白和DJ-1在非小细胞肺癌患者中的诊断及预后价值
Tumour Biol. 2016 Feb;37(2):1949-58. doi: 10.1007/s13277-015-3994-x. Epub 2015 Sep 3.
7
Clinical significance of serum miR-25 in non-small-cell lung cancer.血清miR-25在非小细胞肺癌中的临床意义
Br J Biomed Sci. 2019 Jul;76(3):111-116. doi: 10.1080/09674845.2019.1592915. Epub 2019 May 14.
8
Quantification of free circulating DNA as a diagnostic marker in lung cancer.游离循环DNA作为肺癌诊断标志物的定量分析
J Clin Oncol. 2003 Nov 1;21(21):3902-8. doi: 10.1200/JCO.2003.02.006. Epub 2003 Sep 24.
9
Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer.血浆微小RNA-195在非小细胞肺癌患者中的诊断和预后价值
World J Surg Oncol. 2016 Aug 24;14(1):224. doi: 10.1186/s12957-016-0980-8.
10
Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer.血清 microRNA 特征可用于非小细胞肺癌的早期诊断。
Int J Biol Sci. 2019 Jun 10;15(8):1712-1722. doi: 10.7150/ijbs.33986. eCollection 2019.

引用本文的文献

1
Clinical applications of circulating biomarkers in non-small cell lung cancer.循环生物标志物在非小细胞肺癌中的临床应用
Front Cell Dev Biol. 2024 Aug 21;12:1449232. doi: 10.3389/fcell.2024.1449232. eCollection 2024.
2
Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy.液体活检在癌症免疫治疗中的诊断、监测和预后。
Methods Mol Biol. 2023;2695:127-143. doi: 10.1007/978-1-0716-3346-5_9.
3
Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications.非小细胞肺癌的液体活检：具有多种临床意义的探索。

本文引用的文献

1
Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: the European Early Lung Cancer Project.肺癌患者手术样本中 hTERT mRNA 表达的预后价值：欧洲早期肺癌项目。
Int J Oncol. 2010 Aug;37(2):455-61. doi: 10.3892/ijo_00000694.
2
Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis.循环游离 DNA 定量分析作为肺癌筛查工具的价值：一项荟萃分析。
Lung Cancer. 2010 Aug;69(2):225-31. doi: 10.1016/j.lungcan.2009.11.009. Epub 2009 Dec 11.
3
Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer.
Int J Mol Sci. 2023 Jun 28;24(13):10803. doi: 10.3390/ijms241310803.
4
Quantitative analysis of serum cell-free DNA as a predictive and prognostic marker in breast cancer patients.血清游离DNA作为乳腺癌患者预测和预后标志物的定量分析
Front Oncol. 2023 Jun 22;13:1171412. doi: 10.3389/fonc.2023.1171412. eCollection 2023.
5
Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer.利用我们所有人的基因组：基于血液的液体活检用于癌症早期检测。
View (Beijing). 2022 Jan;3(1). doi: 10.1002/VIW.20200118. Epub 2022 Jan 31.
6
A systematic review and meta-analysis of circulating cell-free DNA as a diagnostic biomarker for non-small cell lung cancer.循环游离DNA作为非小细胞肺癌诊断生物标志物的系统评价与荟萃分析。
J Thorac Dis. 2022 Jun;14(6):2103-2111. doi: 10.21037/jtd-22-646.
7
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.循环无细胞 DNA 作为全球 III 期 ALEX 试验中晚期 ALK+非小细胞肺癌患者的预后生物标志物。
Clin Cancer Res. 2022 May 2;28(9):1800-1808. doi: 10.1158/1078-0432.CCR-21-2840.
8
The influence of biological and lifestyle factors on circulating cell-free DNA in blood plasma.生物和生活方式因素对血浆中循环游离 DNA 的影响。
Elife. 2021 Nov 9;10:e69679. doi: 10.7554/eLife.69679.
9
Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead.非小细胞肺癌免疫治疗的液体活检生物标志物：经验教训与未来之路
J Pers Med. 2021 Sep 28;11(10):971. doi: 10.3390/jpm11100971.
10
The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC.ctDNA和cfDNA围手术期动态变化预测早期非小细胞肺癌复发风险的潜在应用
Front Oncol. 2021 Jul 16;11:671963. doi: 10.3389/fonc.2021.671963. eCollection 2021.
循环 DNA 是非小细胞肺癌患者生存的一种非侵入性预后因素。
Lung Cancer. 2010 May;68(2):283-7. doi: 10.1016/j.lungcan.2009.06.021. Epub 2009 Jul 25.
4
Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.在接受根治性切除的非小细胞肺癌中，人端粒酶逆转录酶（hTERT）mRNA表达增加但端粒酶活性与生存无关。
Anticancer Res. 2009 Apr;29(4):1157-62.
5
[Nuclear Acids In Human Blood Plasma].[人血浆中的核酸]
C R Seances Soc Biol Fil. 1948 Feb;142(3-4):241-3.
6
Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.循环血浆DNA作为非小细胞肺癌的诊断生物标志物
Lung Cancer. 2009 Apr;64(1):92-7. doi: 10.1016/j.lungcan.2008.07.012. Epub 2008 Sep 19.
7
Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study.肺癌计算机断层扫描筛查中的血浆DNA定量：一项前瞻性研究的五年结果
Am J Respir Crit Care Med. 2009 Jan 1;179(1):69-74. doi: 10.1164/rccm.200807-1068OC. Epub 2008 Sep 11.
8
Oncogenic virus-associated neoplasia: a role for cyclin D1 genotypes influencing the age of onset of disease?致癌病毒相关肿瘤形成：细胞周期蛋白D1基因型对疾病发病年龄有影响作用？
Biochem Biophys Res Commun. 2008 May 23;370(1):118-22. doi: 10.1016/j.bbrc.2008.03.039. Epub 2008 Mar 18.
9
Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review.18F-氟脱氧葡萄糖正电子发射断层扫描在非小细胞肺癌中的预测和预后价值：一项系统评价
Cancer. 2007 Oct 15;110(8):1654-64. doi: 10.1002/cncr.22979.
10
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.血浆或血清中循环游离DNA作为致癌作用的生物标志物：实际应用及生物学意义
Mutat Res. 2007 May-Jun;635(2-3):105-117. doi: 10.1016/j.mrrev.2006.11.002. Epub 2007 Jan 25.